+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Usher Syndrome Drug"

Usher Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Usher Syndrome - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Usher Syndrome Type 2- Pipeline Insight, 2024 - Product Thumbnail Image

Usher Syndrome Type 2- Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
From
From
Usher Syndrome Type 2 - Epidemiology Forecast to 2032 - Product Thumbnail Image

Usher Syndrome Type 2 - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Usher Syndrome - Pipeline Review, H1 2020 - Product Thumbnail Image

Usher Syndrome - Pipeline Review, H1 2020

  • Drug Pipelines
  • June 2020
  • 60 Pages
  • Global
From
  • 7 Results (Page 1 of 1)
Loading Indicator

Usher Syndrome Drug is a type of drug used to treat a rare genetic disorder that affects the eyes and ears. It is a form of Central Nervous System (CNS) drug, which is used to treat a variety of neurological conditions. Usher Syndrome is a genetic disorder that affects the development of the eyes and ears, leading to hearing and vision loss. It is the most common cause of combined deaf-blindness in the world. Usher Syndrome Drug is used to treat the symptoms of the disorder, such as hearing loss, vision loss, balance problems, and difficulty with coordination. It is also used to slow the progression of the disorder and to improve the quality of life of those affected. Treatment options include medications, hearing aids, cochlear implants, and vision aids. The Usher Syndrome Drug market is a small but growing market, with a few companies developing treatments for the disorder. These companies include Genzyme, a Sanofi company, which is developing a gene therapy for Usher Syndrome; Spark Therapeutics, which is developing a gene therapy for Usher Syndrome; and ProQR Therapeutics, which is developing a RNA-based therapy for Usher Syndrome. Other companies in the market include Audentes Therapeutics, which is developing a gene therapy for Usher Syndrome, and Otonomy, which is developing a drug for Usher Syndrome. Show Less Read more